To explore the effects of dual therapy with dapagliflozin and exenatide on body weight, body composition, glycaemic variables and systolic blood pressure (SBP) in obese adults without diabetes.
| INTRODUCTION
Globally, more than 1.9 billion adults were overweight [body mass index (BMI) ≥25 kg/m 2 ] in 2014, and of these, 600 million were obese (BMI ≥30 kg/m 2 ). 1 The management of obesity is challenging;
dietary and lifestyle interventions are difficult to sustain, 2, 3 and pharmacotherapies for obesity have generally been ineffective over time, often with troublesome side effects. 4 In contrast to older glucose-lowering medications (sulphonylureas, insulin, thiazolidinediones) that cause body weight gain, 5 newer treatments for type 2 diabetes (T2D) are associated with body weight loss, including selective sodium-glucose co-transporter-2 (SGLT2)
inhibitors (e.g. dapagliflozin, empagliflozin) and glucagon-like peptide-1 receptor agonists (GLP-1RAs; e.g. exenatide, liraglutide). Their glucose-lowering activities are blood glucose-dependent, which minimizes hypoglycaemia, but they produce sustained body weight loss via different mechanisms. 6, 7 SGLT2 inhibitors reduce renal glucose reabsorption, thereby inducing glucosuria. The resulting excretion of calories and mild diuresis are associated with body weight loss and systolic blood pressure (SBP) reduction. [8] [9] [10] GLP-1RAs reduce body weight by decreasing food intake as a result of centrally mediated reduced appetite, with slowed gastric emptying also contributing. 7 SBP reductions also occur with GLP-1RAs. 11 Body weight loss with dapagliflozin, a first-in-class highly selective SGLT2 inhibitor, is consistently observed among patients with T2D receiving oral dapagliflozin 10 mg once daily as monotherapy 12 or with additional glucose-lowering therapies. [13] [14] [15] [16] [17] [18] Mean body weight loss versus placebo, estimated from a network meta-analysis, is −2.2 kg over 24 weeks, 19 mostly accounted for by decreased body fat mass. 14 Clinical data over 2 years show that body weight reduction with dapagliflozin 10 mg once daily is maintained. 20 Exenatide, the first-in-class GLP-1RA, is available in a subcutaneously injected extended-release (2 mg once weekly) formulation. In patients with T2D, mean body weight reduction with exenatide 2 mg once weekly versus placebo, estimated from a mixed treatment comparison meta-analysis, is about −1.6 kg over 24 weeks, 21 mostly as a result of decreased body fat mass. 22 Data from 3 and 5 years of treatment show sustained body weight loss with exenatide 2 mg once weekly. 23, 24 Combination therapy with agents acting via different mechanisms may be the most effective pharmacological approach to treating obesity and addressing evolutionary counter-regulatory mechanisms that maintain body weight. 25 For example, calorie loss through increased urinary glucose excretion with SGLT2 inhibitor treatment may lead to increased appetite, 8 which might be countered by a GLP-1RA. Combining these treatments seems appropriate to enhance and sustain body weight loss.
The present proof-of-concept study examined body weight loss during dual therapy with oral dapagliflozin 10 mg once daily and subcutaneous exenatide 2 mg once weekly in obese participants without diabetes. Body composition, glycaemic control, and blood pressure were also examined. To the best of our knowledge, this is the first report of a randomized controlled trial evaluating initiation of dual therapy with an SGLT2 inhibitor and a GLP1-RA.
| MATERIALS AND METHODS

| Study design and participants
In this collaborative, investigator-sponsored, 24-week, single-centre, randomized, parallel-group, double-blind, placebo-controlled phase IIa study ( Figure 1A) , we evaluated the efficacy and safety of dual therapy with dapagliflozin 10 mg once daily and exenatide 2 mg once weekly in obese participants without diabetes (ClinicalTrials.gov identifier: NCT02313220). The study was conducted at a single centre in 
| Randomization and blinding
Eligible participants were randomized 1 : 1 to receive active treatment or matching placebo using computer codes independently generated by PCG Clinical Services AB (Uppsala, Sweden) and sequentially assigned by the study investigator. Product identity was concealed using sequentially numbered containers. Random assignment to study treatment was stratified by sex and predefined to generate a study population comprising 60% women and 40% men so as to avoid the >80% female enrolment rate commonly observed in obesity trials. 26 For each stratum, block size was randomly either 2 or 4. All personnel remained blinded to treatment allocation codes until database lock after 24 weeks.
| Treatments
All participants received training in self-administration of a subcutaneously injected placebo microsphere preparation (no active ingredient). At randomization, participants assigned to active treatment (dapagliflozin/exenatide) received dapagliflozin 10 mg once daily taken orally each morning and exenatide 2 mg once weekly extended-release formulation administered subcutaneously on the same day each week, at any time of day ( Figure 1A ). Participants assigned to placebo received oral tablets matched to dapagliflozin 10-mg tablets and self-administered the placebo injection. First doses were given on the day of randomization after investigations were completed. Treatment compliance was assessed by quantifying the amount of investigational products returned and participant-reported dosing.
Participants were instructed to continue regular medication (e.g. antihypertensive or lipid-lowering agents) without changing dosages and to take no new prescription or non-prescription medications unless advised by a physician. Participants were requested to report changes in medication or dosages to study investigators.
At each study visit, participants were given a standard leaflet and instructed to follow a balanced diet as per national guidelines. Participants were also advised to exercise moderately (e.g. walking 30 minutes most days); however, diet and exercise modification was not mandated or documented. To evaluate pharmacological effects, major lifestyle changes were not an aim of the study.
| Outcomes
| Efficacy
The primary efficacy endpoint was change in body weight (kg) from baseline (day of randomization) to 24 weeks with dapagliflozin/exenatide versus placebo. Body weight was measured using the same Urine dipstick tests were performed at baseline and showed no overt glucosuria. No further urinary glucose testing was undertaken until 3-hour urine collection during the 24-week OGTT; 24-week urinary glucose was analysed after study completion to maintain blinding until database lock.
Cardiovascular measures included change from baseline in seated SBP, diastolic blood pressure (DBP), which were both measured as the average of two readings and rounded to the nearest 1 mm Hg, and heart rate.
| Safety
Safety and tolerability were assessed over 24 weeks by evaluating the changes from baseline in estimated glomerular filtration rate function and gastrointestinal symptomatology) were captured using prespecified lists of relevant MedDRA preferred terms.
All blood and urine analyses were performed using standard assays at the Clinical Chemistry Laboratory of the Uppsala University Hospital.
| Statistical methods
The primary, secondary and exploratory efficacy endpoints were analysed in the full analysis set (FAS), defined as participants who received ≥1 dose of study medication during the 24-week doubleblind treatment period, who had a baseline value and ≥1 postbaseline value for ≥1 efficacy measure during the double-blind period, and who were not found to have serious protocol non-compliance.
The analysis of safety used the safety analysis set, defined as all randomized participants who received ≥1 dose of study medication.
For primary and secondary endpoints, least-squares (LS) mean changes from baseline to 24 weeks and associated 95% confidence intervals (CIs) and p values for dapagliflozin/exenatide versus placebo differences were derived from a mixed model for repeated measures, with treatment, week, treatment-by-week interaction and sex as categorical fixed covariates, and baseline value as a continuous fixed
covariate. An unstructured matrix for the within-participant error variance-covariance was used. A similar approach was used for changes in HbA1c, blood pressure, heart rate, eGFR and serum lipids. Two dapagliflozin/exenatide-treated participants discontinued because of AEs (abdominal pain and injection-site pruritus/mass).
Three placebo-treated participants discontinued because of AEs (skin ulcer/vasculitis, malaise and dyspnoea/fatigue). One placebo-treated participant withdrew consent and one was excluded for protocol non-compliance (strict low-carbohydrate/high-fat diet that elevated ketones, resulting in FAS exclusion). No withdrawals led to study medication unblinding.
Glycaemic variables, vital signs and renal function were balanced across treatment groups at baseline; however, mean age, body weight, duration of obesity, waist circumference and body fat measures were numerically higher at baseline in the dapagliflozin/ exenatide group than in the placebo group (Table 1) . Overall, more participants had IFG than IGT at baseline (Table 1) .
| Efficacy
| Body weight
Dapagliflozin/exenatide reduced body weight significantly more than placebo ( Figure 2A ; Table 2 ), with a mean difference of −4.13 kg after 24 weeks. The overall percentage reduction in body weight was also significantly greater with dapagliflozin/exenatide than placebo ( Figure 2B ; Table 2 ), and more participants treated with dapagliflozin/ exenatide than placebo achieved body weight reductions ≥5% and ≥10% of their initial weight (Table 2) . Similarly, more participants treated with dapagliflozin/exenatide than placebo achieved any body weight loss or no body weight gain ( Figure 2C,D) . The rate of body weight loss with dapagliflozin/exenatide appeared to be most rapid up to 12 weeks for most participants, although some showed continuing body weight loss to 24 weeks ( Figure 2C ).
| MRI of body composition
Dapagliflozin/exenatide reduced visceral, subcutaneous and total adipose tissue volume, but not lean tissue, significantly more than placebo. Total adipose tissue reduction versus placebo was −4.09 L after 24 weeks (Table 2) . Although dapagliflozin/exenatide significantly reduced percent liver fat from baseline, this reduction was not significantly different from placebo (Table 2) .
| Glycaemic variables
Dapagliflozin/exenatide reduced HbA1c, FPG and 2-hour plasma glucose significantly more than placebo over 24 weeks (Table 2 ; Although the participants did not have diabetes, OGTTs showed that many had abnormal glucose metabolism at baseline, which improved with dapagliflozin/exenatide but not placebo. The proportion of dapagliflozin/exenatide-treated participants with IFG was significantly reduced, from 64.0% at baseline to 34.8% at week 24 (p = .008), and with IGT was significantly reduced from 48.0% to 17.4% (p = .020). Combined, the proportion of participants with prediabetes (any IFG or IGT) significantly decreased from 68.0% to 34.8% (p = .005). In contrast, the corresponding proportions among placebo-treated participants did not change significantly from baseline to 24 weeks (70.8%-85.0%, 33.3%-40.0% and 79.2%-85.0%, respectively; all P > .3; Figure 2G ). Reduction in prediabetes (any IFG or IGT) from baseline to 24 weeks was significantly greater with dapagliflozin/exenatide than placebo (p = .002).
No participants had overt glucosuria at baseline. After 24 weeks, mean urinary glucose was substantially greater with dapagliflozin/ exenatide (50.5 mmol/3 h) than with placebo (0.3 mmol/3 h).
| Vital signs
In this predominantly normotensive population (mean baseline SBP of 134 mm Hg), dapagliflozin/exenatide reduced SBP significantly more than placebo ( Figure 2H) , with a mean difference of −6.7 mm Hg after 24 weeks. No significant differences between dapagliflozin/ exenatide and placebo were observed for DBP or heart rate ( Table 2) .
Some participants, mainly in the dapagliflozin/exenatide group, had pronounced reductions in SBP; however, this did not lead to withdrawal or dose reduction of antihypertensive drugs among participants treated for hypertension. Hypotension was reported in only one placebo-treated participant. New antihypertensive therapies were started in three participants, one in the dapagliflozin/exenatide group and two in the placebo group.
| Safety and tolerability
No meaningful differences between dapagliflozin/exenatide and placebo were observed for eGFR, fasting ketones or serum lipids (Table 3) , or other safety laboratory variables (Table S1 ).
All participants reported at least one AE (Table 3) Urinary tract infections or genital infections were reported in three participants receiving dapagliflozin/exenatide and one participant receiving placebo; no participants reported AEs potentially related to renal impairment/failure (Table 3) .
Gastrointestinal and injection-site-related AEs were more common with dapagliflozin/exenatide than placebo. Gastrointestinal AEs occurred in 16 (64.0%) and 10 (40.0%) of dapagliflozin/exenatideand placebo-treated participants, respectively; nausea was the most frequent, occurring in seven (28.0%) and three (12.0%) participants, respectively. Injection-site-related AEs occurred in 11 (44.0%) and eight (32.0%) of dapagliflozin/exenatide-and placebo-treated participants, respectively (Table 3) . Body weight loss observed after dual therapy appeared to be greater than for dapagliflozin and exenatide individually in previous T2D studies, 12, 21 and these drugs may have contributed additively to the observed body weight loss. Dapagliflozin reduces body weight via increased calorie expenditure through the urine; however, this calorie loss can lead to a compensatory appetite increase. 8 In contrast, exenatide reduces appetite and delays gastric emptying, which both lead to body weight loss. 28 Used together, the mechanisms of the two drugs may have complemented each other; however, the potential for an additive effect cannot be evaluated because this trial did not contain monotherapy comparator arms.
| DISCUSSION
The combination of a selective SGLT2 inhibitor and a GLP-1RA initiated together has not been studied previously, but available data on sequential addition of these drug classes in patients with T2D support this treatment approach. In the randomized, double-blind, placebo-controlled CANVAS study, patients failing treatment for 1 Measured using MRI.
2 Defined as the subcutaneous fat positioned between the hip joint and up to the lower pole of the lungs.
3 Defined as a fasting plasma glucose value ≥5.6 mmol/L measured at time = 0 of an OGTT conducted at the screening visit. 4 Defined as a plasma glucose value ≥7.8 mmol/L measured at time = 120 minutes of an OGTT conducted at the screening visit.
5 Assessed using the Modification of Diet in Renal Disease formula.
6 Hypothyroidism (n = 6), goiter (n = 1), and partial pituitary insufficiency (n = 1).
7 Stopped earlier than 1 month before enrolment. 8 Ongoing or started on the date of randomization or stopped after randomization. IFG defined as an FPG ≥5.6 mmol/L measured just before an OGTT at the 24-week visit. IGT defined as a plasma glucose value ≥7.8 mmol/L measured 2 hours after the start of an OGTT at the 24-week visit; 2-hour PG, measured 2 hours after the start of the OGTT. Hypertension is a frequent comorbidity of obesity and diabetes and an important part of metabolic syndrome. Improving blood pressure control is a common clinical goal for obese patients. Individually, dapagliflozin 10 mg once daily has been associated with SBP reductions ranging from −2.6 to −3. Use of a high-dose GLP-1RA has been suggested as an alternative to combination pharmacotherapy for body weight loss, but the incidence of AEs and need for additional injections may limit its use.
Liraglutide has been approved as a body weight loss therapy at a higher dose (3 mg once daily) than used to treat T2D (1.8 mg once daily). In a placebo-controlled study in obese participants without diabetes receiving liraglutide 3 mg once daily, body weight loss and relative reductions in prediabetes prevalence with liraglutide appeared to be similar to those observed in the present study, but nausea occurred more frequently. 35 Interestingly, dapagliflozin/exenatide dual therapy at higher doses may provide additional body weight loss and metabolic benefits.
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